RAPP · NASDAQ
Rapport Therapeutics, Inc.
$22.25 -3.00 (-11.88%)
Company overview
Rapport Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. Its lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, including peripheral neuropathic pain and bipolar disorder. The company also develops RAP-199, a TARPy8 targeted molecule with differentiated chemical and pharmacokinetic properties, and nicotinic acetylcholine receptor (nAChR) programs, such as a6 nAChR to treat chronic pain and a9a10 nAChR for the treatment of hearing disorders. The company was formerly known as Precision Neuroscience NewCo, Inc.
- Sector
- Healthcare
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Market cap
- $1.1B
- Employees
- 69
- Headquarters
- Boston, DE
- Website
- rapportrx.com
- CEO
- Abraham N. Ceesay
- Listed
- June 7, 2024
- P/E
- -8.69
- Dividend yield
- 0.00%
Company financials
- Revenue
- $20M
- Gross profit
- $19.5M
- Operating income
- -$122M
- EBITDA
- -$118M
- Net income
- -$107M
- EPS
- -$2.60
- Total assets
- $498M
- Total debt
- $10.8M
- Gross margin
- 97.54%
- Net margin
- -536.39%
- Earnings yield
- -11.51%
RAPP
1D
NASDAQ
O26.02H27.95L25.08C25.33-0.60 (-2.31%)Vol1.04M